A detailed history of Bell Investment Advisors, Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Bell Investment Advisors, Inc holds 52 shares of DNLI stock, worth $1,257. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52
Previous 52 -0.0%
Holding current value
$1,257
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

SELL
$15.83 - $23.35 $395 - $583
-25 Reduced 32.47%
52 $1,000
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $550 - $788
34 Added 79.07%
77 $1,000
Q3 2023

Nov 08, 2023

SELL
$20.63 - $30.17 $433 - $633
-21 Reduced 32.81%
43 $0
Q2 2022

Aug 12, 2022

BUY
$20.88 - $35.19 $1,106 - $1,865
53 Added 481.82%
64 $2,000
Q4 2021

Feb 14, 2022

SELL
$42.59 - $55.02 $553 - $715
-13 Reduced 54.17%
11 $0
Q3 2021

Nov 12, 2021

BUY
$48.48 - $78.23 $1,163 - $1,877
24 New
24 $1,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.24B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Bell Investment Advisors, Inc Portfolio

Follow Bell Investment Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bell Investment Advisors, Inc with notifications on news.